Abstract
On January 1, 2006, Medicare Part D prescription drug coverage was initiated. Concern was immediately voiced by the American Association of Retired Persons (AARP) and Families USA that, in response to this program, the pharmaceutical industry may raise prices for drugs most often used by the elderly. This article examines the ethical implications of a revenue-maximizing pricing strategy in an industry in which third party financing mitigates an end product’s true cost to the user. The perspectives of three stakeholder groups are examined: the elderly, as consumers of prescription drugs, the pharmaceutical industry, as product manufacturer and beneficiary of derived profits, and the total U.S. population, as the ultimate payer for the program via tax revenues. Key questions explored include the relationships among price strategy and access to drugs at both the micro (Medicare cohort) and macro (total population) levels, and on drug development or enhancement. The role of profit in a capitalism-based health care system is also examined. Hospital industry impact on these same stakeholder groups in response to the original 1965 Medicare law is used to compare and contrast possible outcomes of the new drug program. It is predicted that pharmaceutical firms will mimic the hospital industry, adopting a price maximizing strategy for drugs covered by the program. In the process, a utilitarian effect occurs: the benefits of increased access and diffusion of drugs counterbalance inequities in financing Medicare Part D.
Similar content being viewed by others
References
Abboud, L.: 2004, ‹Abbott’s Pricing on AIDS Drug Prompts Call for an Early Generic’, Wall Street Journal, May 13, D.7
Adams C., V. Brantner 2006, Estimating the Cost of New Drug Development: Is It Really Worth $802 Million? Health Affairs, 25(2), 420–428
Anderson O. 1985, Health Services in the United States: A Growth Enterprise Since 1875. Ann Arbor: Health Administration Press
Anonymous: 2005, ‹Medicare’, Social Security Bulletin, 35–50
Balotsky E. R. 2005, Is It Resources, Habit or Both: Interpreting Twenty Years of Hospital Strategic Response to Prospective Payment. Health Care Management Review, 30(4), 337–346
Biles B., G. Dallek, L. Nicholas 2004, Medicare Advantage: Déjà Vu All Over Again? Health Affairs, 23, 586–597
Binder, C., L. Gross, D. Gross, S. Schondelmeyer and S.␣Raetzman: 2006, ‹Trends in Manufacturer Prices of Prescription Drugs Used by Older Americans’, Available at http://www.aarp.org/research/health/drugs/aresearch-import-869-2005-06-IB69.html
Bishop C., L. Dubay 1991, Medicare Patient Access to Posthospital Skilled Nursing Facility Care. Inquiry – Blue Cross and Blue Shield Association, 28(4), 345–356
Callahan D. 2006, Curing, Caring and Coping. America, 194(3), 12–16
Cohen E. 2004, The Politics and Realities of Medicare. Public Interest, 156, 37–50
DeFrances C., M. Podgornik 2006, 2004 National Hospital Discharge Survey. Advance Data from Vital and Health Statistics, 371, 1–20
DeParle N. 2002: As Good as It Gets? The Future of Medicare+ Choice. Journal of Health Politics, Policy and Law, 27(3), 495–513
Dor A. 1989, The Cost of Medicare Patients in Nursing Homes in the United States: A Multiple Output Analysis. Journal of Health Economics, 8(3), 253–270
Druss B., S. Marcus, M. Olfson, H. Pincus 2004, Listening to Generic Prozac: Winners, Losers, and Sideliners. Health Affairs, 23(5), 210–216
Frank R. 2001, Prescription Drug Prices: Why do Some Pay More than Others do? Health Affairs, 20(2), 115–128
Freudenheim, M.: 2006, ‹A Windfall from Shifts to Medicare’, New York Times, Available at http://www.nytimes.com/2006/07/18/business/18place.html
Friedman, M.: 1970, ‹The Social Responsibility of Business is to Increase Profits’, The New York Times Magazine, September 13
Gasorek D. 2005, Pharma Ethics: Who Sees the Halo? Pharmaceutical Executive, 25(6), 68–72
Gebhart F. 2004, How do Manufacturers Set Drug Prices? Here’s a Look. Drug Topics, 148, 64
Gold M. 2005, Private Plans in Medicare: Another Look. Health Affairs, 24(5), 1302–1310
Gottlieb S. 2005, Treating and Curing Diseases. Vital Speeches of the Day, 72(5), 147–151
Gresham, L.: 2006, ‹Riding the Generics Wave to Drug Savings’, Employee Benefit News, June 15, 1
Hansen C. 2004, Who are the Drug Companies Hurting. Vital Speeches of the Day, 70(10), 301–305
Heavey, S.: 2006, ‹U.S. Says Medicare Drug Plan Passes 30 Million Goal’, Available at http://today.reuters.com/misc, April 24, 2006
Heffler, S., S. Smith, S. Keehan, K. Clemens, C. Truffer and M. Zezza: 2004, ‹Health Spending Projections Through 2013’, Health Affairs, Web Exclusives, W79–W92
Hislop R. 2001, The Politics of Medicare and Prescription Drug Costs. Human Rights, 28(2), 15–16
Laschober, M., M. Kitchman, P. Neuman and A. Strabic: 2003, ‹Trends in Medicare Supplemental Insurance and Prescription Drug Coverage’, Health Affairs, Web Exclusives, W127
Levya-Gardner K. 2006, Drug Plans: Balance Quality, Affordability. Credit Union Magazine, 72(7), 48
Mahan, D.: 2006, ‹Big Dollars, Little Sense: Rising Medicare Prescription Drug Prices’, Available at http://www.familiesusa.org/resources/publications/reports/big-dollars-little-sense.html
Maitland I. 2002, Priceless Goods: How Should Life-Saving Drugs be Priced? Business Ethics Quarterly, 12(4), 451–480
Malloy J., D. Skinner 1984, Medicare on the Critical List. Harvard Business Review, 62(6), 122–135
Mokhiber R., R. Weissman 2003, Multiple Corporate Personality Disorder: The 10 Worst Corporations of 2003. Multinational Monitor, 24(12), 9–20
Mole R. 2005, Big ‹Bad’ Pharma. Journal of Medical Marketing, 5(3), 261–263
National Health Care Expenditures: 1960–2004, Available at http://www.cms.hhs.gov/nationalhealthexpenddata/downloads/tables.pdf
National Health Care Expenditures Projections: 2005–2015, Available at http://www.cms.hhs.gov/nationalhealthexpenddata/downloads/proj2005.pdf
Newhouse J. 2004, How Much Should Medicare Pay for Drugs. Health Affairs, 23(1), 89–101
Nichols L. M., P. B. Ginsburg, R. A. Berenson, J. Christianson, R. E. Hurley 2004, Are Market Forces Strong Enough to Deliver Efficient Health Care Systems, Confidence is Waning. Health Affairs, 23(2), 8–21
Okunade A. 2006. Medicare Reform: Successes and Current Challenges of the New Part D Program. Business Perspectives, 18(1), 32–37
Porth S., G. Sillup 2005, Good News Bad News. Pharmaceutical Executive, 25(4), 106–110
Safran D., P. Neuman, C. Schoen, M. Kitchman, B. Cooper, I. Wilson, A. Li, H. Chang, W. Rogers 2005, Prescription Drug Coverage and Seniors: Findings from a 2003 National Survey. Health Affairs, 24, 152–166
Santangelo M. 2006, Historical Perspective on Adding Drugs to Medicare. Health Care Financing Review, 27(2), 25–33
Santerre R., J. Vernon, C. Giaccotto 2006, The Impact of Indirect Government Controls on U.S. Drug Prices and R&D. Cato Journal, 26(1), 143–165
Scanlon W. 2006, The Future of Medicare Hospital Payment. Health Affairs, 25(1), 70–80
Sear A. 2004, Effects of Medicare BBA Spending Reductions on the Profitability of General Acute Care Hospitals. Journal of Healthcare Management, 49(2), 119–133
Sharfstein S. S., L. M. Koran 1990, Mental Health Services. In A. R. Kovner (Ed.), Health Care Delivery in the United States (4th ed.), New York: Springer, 209–239
Silvers J. 2001, The Role of Capital Markets in Restructuring Health Care. Journal of Health Politics, Policy and Law, 26(5), 1019–1030
Spinello R. 1992, Ethics, Pricing and the Pharmaceutical Industry. Journal of Business Ethics, 11(8), 617–626
Starr P. 1982, The Social Transformation of American Medicine. New York: Basic
Straube B. 2005, How Changes in the Medicare Coverage Process have Facilitated the Spread of New Technologies. Health Affairs, 24, 314–316
Studdert D., M. Mello, T. Brennan 2004, Financial Conflicts of Interest in Physicians’ Relationships with the Pharmaceutical Industry: Self-Regulation in the Shadow of Federal Prosecution. The New England Journal of Medicine, 351(18), 1891–1900
Szabo, L.: 2006, ‹Prices Soar for Cancer Drugs’, USA Today, Available at http://www.comcast.net/finance/usatoday/index.jsp?fn=/2006/07/10/264970.html
Towse A. 2003, The Efficient Use of Pharmaceuticals: Does Europe have Any Lessons for a Medicare Drug Benefit? Health Affairs, 22(3), 42–50
Verschoor C. 2006, Pharma Industry has Many Ethical Issues. Strategic Finance, 87(8), 16–18
Vladeck B. 2004, The Struggle for the Soul of Medicare. The Journal of Law, Medicine & Ethics, 32(3), 410–415
White J., S. Taft 2004, Frameworks for Teaching and Learning Business Ethics Within the Global Context: Background of Ethical Theories. Journal of Management Education, 28(4), 463–477
Wiggins S., R. Maness 2004, Price Competition in Pharmaceutical: The Case of Anti-Infectives. Economic Inquiry, 42(2), 247–263
Wing K. R. 1985, The Law and the Public’s Health (2nd ed.). Ann Arbor: Health Administration Press
Worzala C., J. Pettengill, J. Ashby 2003, Challenges and Opportunities for Medicare’s Original Prospective Payment. Health Affairs, 22(6), 175–182
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balotsky, E.R. Where Strategy and Ethics Converge: Pharmaceutical Industry Pricing Policy for Medicare Part D Beneficiaries. J Bus Ethics 84 (Suppl 1), 75–88 (2009). https://doi.org/10.1007/s10551-008-9682-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10551-008-9682-7